POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS, AND RELATED METHODS OF USE

• US 20100247669A1
• Filed: 03/29/2010
• Published: 09/30/2010
• Est. Priority Date: 03/30/2009
• Status: Abandoned Application

• Current Assignee: Cerulean Pharma Inc. (Daré Bioscience, Inc.)
• Original Assignee: Cerulean Pharma Inc. (Daré Bioscience, Inc.)
• Inventors: Reiter, Lawrence Alan, Ng, Pei-Sze, Gangal, Geeti, Eliasof, Scott, Crawford, Thomas C.
• Application Number:
  US12/748,669
• Publication Number:
  US 20100247669A1
• Time in Patent Office: Days
• US Class Current: 424/501
• CPC Class Codes: A61K 31/337 having four-membered rings, e.g. taxol
• CPC Class Codes: A61K 31/675 having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• CPC Class Codes: A61K 31/69 Boron compounds
• CPC Class Codes: A61K 31/704 attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin digitoxin A61K31/7048
• CPC Class Codes: A61K 31/765 Polymers containing oxygen
• CPC Class Codes: A61K 31/80 Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
• CPC Class Codes: A61K 47/593 Polyesters, e.g. PLGA or polylactide-co-glycolide
• CPC Class Codes: A61K 9/14 Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51
• CPC Class Codes: A61K 9/1647 Polyesters, e.g. poly(lactide-co-glycolide)
• CPC Class Codes: A61K 9/19 lyophilised , i.e. freeze-dried, solutions or dispersions lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00
• CPC Class Codes: A61K 9/5138 obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Abstract

Described herein are polymer-agent conjugates and particles, which can be used, for example, in the treatment of cancer. Also described herein are mixtures, compositions and dosage forms containing the particles, methods of using the particles (e.g., to treat a disorder), kits including the polymer-agent conjugates and particles, methods of making the polymer-agent conjugates and particles, methods of storing the particles and methods of analyzing the particles.

Claims

1. (canceled)

2. A particle, comprising:

a) a plurality of hydrophobic polymer-pharmaceutically active agent represented by Formula (A) conjugates, wherein

i) each hydrophobic polymer-pharmaceutically active agent represented by Formula (A) conjugate of said plurality comprises a hydrophobic polymer attached to a pharmaceutically active agent represented by Formula (A);

5. The particle of claim 2, comprising:

a) a plurality of hydrophobic polymer-pharmaceutically active agent represented by Formula (A) conjugates, wherein

i) each hydrophobic polymer-pharmaceutically active agent represented by Formula (A) conjugate of said plurality comprises a hydrophobic polymer attached to a pharmaceutically active agent of Formula (A),

ii) said hydrophobic polymer attached to the pharmaceutically active agent of Formula (A) can be a homopolymer or a polymer made up of more than one kind of monomeric subunit,

iii) said hydrophobic polymer attached to said pharmaceutically active agent of Formula (A) has a weight average molecular weight of about 4-15 kD,

iv) said pharmaceutically active agent of Formula (A) is about 1-30 weight % of said particle, and

v) said plurality of hydrophobic polymer-pharmaceutically active agent represented by Formula (A) conjugates is about 25-80 weight % of said particle;

b) a plurality of hydrophilic-hydrophobic polymers, wherein

i) each of said hydrophilic-hydrophobic polymers of said plurality comprises a hydrophilic portion attached to a hydrophobic portion,

ii) said hydrophilic-portion has a weight average molecular weight of about 1-6 kD, wherein

if the weight average molecular weight of said hydrophilic portion is about 1-3 kD, the ratio of the weight average molecular weight of said hydrophilic portion to the weight average molecular weight of said hydrophobic portion is between 1;

4-1;

7, and if the weight average molecular weight of said hydrophilic portion is about 4-6 kD, the ratio of the weight average molecular weight of said hydrophilic portion to the weight average molecular weight of said hydrophobic portion is between 1;

2-1;

3; and

iii) said plurality of hydrophilic-hydrophobic polymers is about 5-30 weight % of said particle; and

c) a surfactant, wherein said surfactant is about 15-35 weight % of said particle;

and

wherein;

the diameter of said particle is less than about 200 nm.

8. The particle of claim 2, comprising:

a) a plurality of hydrophobic polymer-pharmaceutically active agent represented by Formula (A) conjugates, wherein

i) each hydrophobic polymer-pharmaceutically active agent represented by Formula (A) conjugate of said plurality comprises a hydrophobic polymer attached to a pharmaceutically active agent of Formula (A),

ii) said hydrophobic polymer attached to said pharmaceutically active agent of Formula (A) can be a homopolymer or a polymer made up of more than one kind of monomeric subunit,

iii) said hydrophobic polymer attached to said pharmaceutically active agent of Formula (A) has a weight average molecular weight of about 4-15 kD,

iv) said pharmaceutically active agent of Formula (A) is about 1-30 weight % of said particle and

v) said plurality of hydrophobic polymer-pharmaceutically active agent represented by Formula (A) conjugates is about 35-80 weight % of said particle;

b) a plurality of hydrophilic-hydrophobic polymers, wherein

i) each of said hydrophilic-hydrophobic polymers of said plurality comprises a hydrophilic portion attached to a hydrophobic portion, and

ii) said hydrophilic portion has a weight average molecular weight of about 2-6 kD and said hydrophobic portion has a weight average molecular weight of between about 8-13 kD,

iii) said plurality of hydrophilic-hydrophobic polymers is about 10-25 weight % of said particle;

iv) said hydrophilic portion of said hydrophilic-hydrophobic polymer terminates in an OMe, and

c) a surfactant, wherein said surfactant is about 15-35 weight % of said particle;

wherein;

said particle further comprises a hydrophobic polymer having a terminal acyl moiety; and

the diameter of said particle is less than about 200 nm.

11. A method of making the particle of claim 2, comprising:

providing an organic solution comprising;

a) a plurality of hydrophobic-polymer pharmaceutically active agent represented by Formula (A) conjugates, wherein

i) each hydrophobic polymer-pharmaceutically active agent represented by Formula (A) conjugate of said plurality comprises a hydrophobic polymer attached to a pharmaceutically active agent of Formula (A),

ii) said hydrophobic polymer attached to said pharmaceutically active agent of Formula (A) can be a homopolymer or a polymer made up of more than one kind of monomeric subunit,

iii) said hydrophobic polymer attached to said pharmaceutically active agent of Formula (A) has a weight average molecular weight of about 4-15 kD,

iv) said pharmaceutically active agent represented by Formula (A) is about 1-30 weight % of said particle and

v) said plurality of hydrophobic polymer-pharmaceutically active agent represented by Formula (A) conjugates is about 25-80 weight % of said particle;

b) a plurality of hydrophilic-hydrophobic polymers, wherein

i) each of said hydrophilic-hydrophobic polymers of said plurality comprises a hydrophilic portion attached to a hydrophobic portion,

ii) said hydrophilic portion has a weight average molecular weight of about 1-6 kD, and

iii) said plurality of hydrophilic-hydrophobic polymers is about 5-30 weight % of said particle;

and

combining said organic solution with an aqueous solution comprising a solvent to provide said particles.

14. A pharmaceutically acceptable composition comprising a plurality of particles of claim 2 and an additional component.

15. A kit comprising a plurality of particles of claim 2.

16. A single dosage unit comprising a plurality of particles of claim 2.

17. A method of treating a subject having a disorder comprising administering to said subject an effective amount of particles of claim 2.

18. The particle of claim 2, comprising:

a) a plurality of hydrophobic polymer-pharmaceutically active agent represented by Formula (A) conjugates, wherein

i) each hydrophobic polymer-pharmaceutically active agent represented by Formula (A) conjugate of said plurality comprises a hydrophobic polymer attached to a pharmaceutically active agent of Formula (A),

ii) said hydrophobic polymer attached to said pharmaceutically active agent of Formula (A) can be a homopolymer or a polymer made up of more than one kind of monomeric subunit,

iii) said hydrophobic polymer attached to said pharmaceutically active agent of Formula (A) has a weight average molecular weight of about 4-15 kD,

iv) said pharmaceutically active agent of Formula (A) is about 1-30 weight % of said particle and

v) said plurality of hydrophobic polymer-pharmaceutically active agent represented by Formula (A) conjugates is about 25-80 weight % of said particle;

b) a plurality of PEG-hydrophobic polymers, wherein

i) each of said PEG-hydrophobic polymers of said plurality comprises a PEG portion attached to a hydrophobic portion,

ii) said PEG portion has a weight average molecular weight of about 1-6 kD, and

iii) said plurality of PEG-hydrophobic polymers is about 5-30 weight % of said particle;

and

c) PVA, wherein said PVA has a weight average molecular weight of about 5-45 kD and is about 15-35 weight of said particle; and

wherein;

the diameter of said particle is less than about 200 nm.

21. The particle of claim 18, comprising:

a) a plurality of hydrophobic polymer-pharmaceutically active agent represented by Formula (A) conjugates;

wherein

i) each hydrophobic polymer-pharmaceutically active agent represented by Formula (A) conjugate of said plurality comprises a hydrophobic polymer attached to a pharmaceutically active agent of Formula (A),

ii) the hydrophobic polymer is made up of a first and a second type of monomeric subunit, and the ration of the first to second type of monomeric subunit is said hydrophobic polymer attached to said pharmaceutically active agent of Formula (A) is from about 25;

75 to about 75;

25,

iii) said hydrophobic polymer attached to said pharmaceutically active agent of Formula (A) has a weight average molecular weight of about 4-15 kD,

iv) said pharmaceutically active agent of Formula (A) is about 1-30 weight % of said particle and

v) said plurality of hydrophobic polymer-pharmaceutically active agent represented by Formula (A) conjugates is about 25-80 weight % of said particle;

b) a plurality of PEG-hydrophobic polymers, wherein

i) each of said PEG-hydrophobic polymers of said plurality comprises a PEG portion attached to a hydrophobic portion,

ii) said PEG portion has a weight average molecular weight of about 1-6 kD, wherein

if the weight average molecular weight said PEG portion is about 1-3 kD, the ratio of the weight average molecular weight of said PEG portion to the weight average molecular weight of said hydrophobic portion is between 1;

3-1;

7, and if the weight average molecular weight of said PEG portion is about 4-6 kD, the ratio of the weight average molecular weight of said PEG portion to the weight average molecular weight of said hydrophobic portion is between 1;

1-1;

4; and

iii) said plurality of PEG-hydrophilic polymers is about 5-30 weight % of said particle; and

c) PVA, wherein said PVA has a weight average molecular weight of about 5-45 kD and is about 15-35 weight % of said particle; and

wherein;

the diameter of said particle is less than about 200 nm.

24. The particle of claim 18, comprising:

a) a plurality of hydrophobic polymer-pharmaceutically active agent represented by Formula (A) conjugates, wherein

i) each hydrophobic polymer-pharmaceutically active agent represented by Formula (A) conjugate of said plurality comprises a hydrophobic polymer attached to a pharmaceutically active agent of Formula (A),

ii) the hydrophobic polymer is made up of a first and a second type of monomeric subunit, and the ratio of the first to the second type of monomeric subunit in said hydrophobic polymer attached to said pharmaceutically active agent of Formula (A) is from about 25;

75 to about 75;

25,

iii) said hydrophobic polymer attached to said pharmaceutically active agent of Formula (A) has a weight average molecular weight of about 4-15 kD,

iv) said pharmaceutically active agent represented by Formula (A) is about 1-30 weight % of said particle and

v) said plurality of hydrophobic polymer-pharmaceutically active agent of Formula (A) conjugates is about 35-80 weight % of said particle;

b) a plurality of PEG-hydrophobic polymers, wherein

i) each of said PEG-hydrophobic polymers of said plurality comprises a PEG portion attached to a hydrophobic portion, and

ii) said PEG portion has a weight average molecular weight of about 2-6 kD and said hydrophobic portion has a weight average molecular weight of between about 8-13 kD,

iii) said plurality of PEG-hydrophobic polymers is about 10-25 weight % of said particle;

iv) said PEG portion of said PEG-hydrophilic polymer terminates in an OMe, and

c) PVA, wherein said PVA has a weight average molecular weight of about 23-26 kD and is about 15-35 weight % of said particle;

wherein;

the particle further comprises a hydrophobic polymer having a terminal acyl moiety; and

the diameter of said particle is less than about 200 nm.

34. The particle of claim 2 comprising:

a) a plurality of PLGA-pharmaceutically active agent represented by Formula (A) conjugates, wherein

i) each PLGA-pharmaceutically active agent represented by Formula (A) conjugate of said plurality comprises a PLGA polymer attached to a pharmaceutically active agent of Formula (A),

ii) the ratio of lactic acid to glycolic acid in said PLGA polymer attached to said pharmaceutically active agent of Formula (A) is from about 25;

75 to about 75;

25,

iii) said PLGA polymer attached to said pharmaceutically active agent of Formula (A) has a weight average molecular weight of about 4-15 kD,

iv) said pharmaceutically active agent of Formula (A) is about 1-30 weight % of said particle and

v) said plurality of PLGA-pharmaceutically active agent represented by Formula (A) conjugates is about 25-80 weight % of said particle;

b) a plurality of PEG-PLGA polymers, wherein

i) each of said PEG-PLGA polymers of said plurality comprises a PEG portion attached to a PLGA portion,

ii) said PEG portion has a weight average molecular weight of about 1-6 kD, and

iii) said plurality of PEG-PLGA polymers is about 5-30 weight % of said particle; and

c) PVA, wherein said PVA has a weight average molecular weight of about 5-45 kD and is about 15-35 weight % of said particle; and

wherein;

the diameter of said particle is less than about 200 nm.

37. The particle of claim 34, comprising:

a) a plurality of PLGA-pharmaceutically active agent represented by Formula (A) conjugates, wherein

i) each PLGA-pharmaceutically active agent represented by Formula (A) conjugate of said plurality comprises a PLGA polymer attached to a pharmaceutically active agent of Formula (A),

ii) the ratio of lactic acid to glycolic acid in said PLGA polymer attached to said pharmaceutically active agent of Formula (A) is from about 25;

75 to about 75;

25,

iii) said PLGA polymer attached to said pharmaceutically active agent of Formula (A) has a weight average molecular weight of about 4-15 kD,

iv) said pharmaceutically active agent of Formula (A) is about 1-30 weight % of said particle and

v) said plurality of PLGA-pharmaceutically active agent represented by Formula (A) conjugates is about 25-80 weight % of said particle;

b) a plurality of PEG-PLGA polymers, wherein

i) each of said PEG-PLGA polymers of said plurality comprises a PEG portion attached to a PLGA portion,

ii) said PEG portion has a weight average molecular weight of about 1-6 kD, wherein

if the weight average molecular weight of said PEG portion is about 1-3 kD, the ratio of the weight average molecular weight of said PEG portion to the weight average molecular weight of said PLGA portion is between 1;

3-1;

7, and if the weight average molecular weight of said PEG portion is about 4-6 kD, the ratio of the weight average molecular weight of said PEG portion to the weight average molecular weight of said PLGA portion is between 1;

1-1;

4; and

iii) said plurality of PEG-PLGA polymers is about 5-30 weight % of said particle; and

c) PVA, wherein

said PVA has a weight average molecular weight of about 5-45 kD and is about 15-35 weight % of said particle; and

wherein;

the diameter of said particle is less than about 200 nm.

40. The particle of claim 34, comprising:

a) a plurality of PLGA-pharmaceutically active agent represented by Formula (A) conjugates, wherein

i) each PLGA-pharmaceutically active agent represented by Formula (A) conjugate of said plurality comprises a PLGA polymer attached to a pharmaceutically active agent of Formula (A),

ii) the ratio of lactic acid to glycolic acid in said PLGA polymer attached to said pharmaceutically active agent of Formula (A) is from about 25;

75 to about 75;

25,

iii) said PLGA polymer attached to said pharmaceutically active agent of Formula (A) has a weight average molecular weight of about 4-15 kD,

iv) said pharmaceutically active agent of Formula (A) is about 1-30 weight % of said particle and

v) said plurality of PLGA-pharmaceutically active agent represented by Formula (A) conjugates is about 35-80 weight % of said particle;

b) a plurality of PEG-PLGA polymers, wherein

i) each of said PEG-PLGA polymers of said plurality comprises a PEG portion attached to a PLGA portion, and

ii) said PEG portion has a weight average molecular weight of about 2-6 kD and said PLGA portion has a weight average molecular weight of between about 8-13 kD,

iii) said plurality of PEG-PLGA polymers is about 10-25 weight % of said particle;

iv) said PEG portion of said PEG-PLGA polymer terminates in an OMe,

and

c) PVA, wherein said PVA has a weight-average molecular weight of about 23-26 kD and is about 15-35 weight % of said particle;

wherein;

said particle further comprises PLGA having a terminal acyl moiety; and

the diameter of said particle is less than about 200 nm.

50. The particle of claim 2, wherein:

P is R⁷—

C(O)—

, where R⁷ is heteroaryl or heteroarylalkyl;

X² is —

C(O)—

NH—

;

R′

is hydrogen or alkyl, or R′

forms together with the adjacent R¹, or when A is zero, forms together with the adjacent R², a nitrogen-containing mono-, bi- or tri-cyclic, saturated or partially saturated ring system having 4-14 ring members, that can be optionally substituted by one or two of keto, hydroxy, alkyl, aryl, aralkyl, alkoxy or aryloxy;

R¹, at each occurrence, is independently one of hydrogen;

alkyl, cycloalkyl, aryl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or —

CH₂—

R⁵, where the ring portion of any of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted;

R² is one of hydrogen, alkyl, cycloalkyl, aryl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or —

CH₂—

R⁵, where the ring portion of any of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted;

R³ is one of hydrogen, alkyl, cycloalkyl, aryl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or —

CH₂—

R⁵, where the ring portion of any of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted;

R⁵, in each instance, is one of aryl, aralkyl, alkaryl, cycloalkyl, a 5-10 membered saturated, partially unsaturated or aromatic heterocycle or —

W—

R⁶, where W Is a chalcogen; and

R⁶ is alkyl, where the ring portion of any of said aryl, aralkyl, alkaryl or heterocycle can be optionally substituted;

Z¹ and Z² are independently one of alkyl, hydroxy, alkoxy, or aryloxy, or together Z¹ and Z² form a moiety derived from a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms, and optionally, a heteroatom or heteroatoms which can be N, S, or 0; and

A is zero.

51. The particle of claim 2, wherein

P is hydrogen or an amino group protecting moiety;

A is zero;

X² is —

C(O)—

NH—

;

R′

is hydrogen or C_1-8 alkyl;

R² is —

CH₂—

R⁵;

R³ is C₄ alkyl;

R⁵ is aryl or cycloalkyl, wherein R⁵ is optionally substituted by one or two substituents independently selected from the group consisting of C_1-6 alkyl, C_3-8 cycloalkyl, C_1-6 alkyl(C_3-8)cycloalkyl, C_2-8 alkenyl, C_2-8 alkynyl, cyano;

amino, C_1-6 alkylamino, di(C_1-6)alkylamino, benzylamino, dibenzylamino, nitro, carboxy, carbo(C_1-6)alkoxy, trifluoromethyl, halogen, C_1-6 alkoxy, C_6-10 aryl, C_6-10 aryl(C_1-6)alkyl, C_6-10 aryl(C_1-6)alkoxy, hydroxy, C_1-6 alkylthio, C_1-6 alkylsulfinyl, C_1-6 alkylsulfonyl, C_6-10 arylthio, C_6-10 arylsulfinyl, C_6-10 arylsulfonyl, C_1-6 alkyl(C_6-10)aryl, and halo(C_6-10)aryl;

Z¹ and Z² are independently one of alkyl, hydroxy, alkoxy, or aryloxy, or together Z¹ and Z² form a moiety derived from a dihydroxy compound having at least two hydroxy groups separated by at least two connecting atoms in a chain or ring, said chain or ring comprising carbon atoms, and optionally, a heteroatom or heteroatoms which can be N, S, or 0; and

A is zero.

52. The particle of claim 2, wherein:

P is hydrogen or an amino-group protecting moiety;

R′

is hydrogen or alkyl;

A is 0, 1, or 2;

R¹, R², and R³ are each independently hydrogen, alkyl, cycloalkyl, aryl, or —

C₂—

R⁵;

R⁵, in each instance, is aryl, aralkyl, alkaryl, cycloalkyl, heterocyclyl, heteroaryl, or —

W—

R⁶, where W is a chalcogen and R⁶ is alkyl;

wherein the ring portion of any said aryl, aralkyl, alkaryl, cycloalkyl, heterocyclyl, or heteroaryl in R¹, R², R³, or R⁵ can be optionally substituted; and

Z¹ and Z² together form a moiety derived from a sugar, wherein the atom attached to boron in each case is an oxygen atom.

53. The particle of claim 2, wherein:

P is R′

or R⁷—

C(═

O)—

or R⁷—

SO₂-, wherein R⁷ selected from the group consisting of

54. The particle of claim 2, wherein the pharmaceutically active agent is represented by Formula (2A)

55. The particle of claim 2, wherein the compound of formula ((A)) is represented by the following structural formula:

57. The pharmaceutically acceptable composition of claim 14, wherein said additional component is a lyoprotectant.

3-4. -4. (canceled)

6-7. -7. (canceled)

9-10. -10. (canceled)

12-13. -13. (canceled)

19-20. -20. (canceled)

22-23. -23. (canceled)

25-33. -33. (canceled)

35-36. -36. (canceled)

38-39. -39. (canceled)

41-49. -49. (canceled)

56. (canceled)

58-94. -94. (canceled)

95. A polymer-agent conjugate, wherein said agent is a boron-containing pharmaceutically active agent, comprising:

a hydrophobic polymer; and

the boron-containing pharmaceutically active agent attached to said polymer.

96-121. -121. (canceled)